Análise do FDA | Sobrevida geral de pacientes com câncer de mama positivo para receptor hormonal, HER2 negativo, metastático ou avançado tratado com inibidor de quinase 4/6 dependente de ciclina com fulvestrante.

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis – The Lancet Oncology (link para o resumo – $ para o texto completo)

Comentário no Twitter

A pooled analysis of phase III trials of fulvestrant plus either CDK4/6 inh or placebo in pts with HR+/HER2- advanced-stage #breastcancer shows an mOS benefit of 7.1 months (over a mFU of 43.7 months) favouring CDK4/6i (HR 0.77, 95% CI 0.68–0.88): https://t.co/ZMa0J8gS8Q #bcsm

— NatureRevClinOncol (@NatRevClinOncol) October 21, 2021